US Patent

US9808587 — Dose counter for inhaler having an anti-reverse rotation actuator

Formulation · Assigned to Teva Pharmaceuticals Ireland · Expires 2031-05-18 · 5y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a dose counter for an inhaler that prevents the medicament canister from being rotated in reverse.

USPTO Abstract

An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.

Drugs covered by this patent

Patent Metadata

Patent number
US9808587
Jurisdiction
US
Classification
Formulation
Expires
2031-05-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Teva Pharmaceuticals Ireland
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.